AG-014699 (Rucaparib) is an intraveneously-administered, azepinone-indole-based inhibitor of PARP 1 and 2 (Ki = 1.4 nM) [1] AG-014699 induces selective cytotoxicity in tumor cells defective in homologous recombination repair (HRR) through BRCA1 and 2 mutation and non-BRCA mutated HRR defects. It is a potent chemosensitizer of temozolomide (3 to 10 fold) and topotecan (1.5 to 2.3 fold) antitumor activity in neuroblastoma cells. [2, 3]

---

Technical information:

Chemical Formula:		C19H18FN3O.H3PO4
CAS #:		459868-92-9
Molecular Weight:		421.36
Purity:		> 98%
Appearance:		Yellow
Chemical Name:		8-Fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one phosphate
Solubility:		Up to 100 mM in DMSO
Synonyms:		AG-014699, AG014699, AG-14699, AG14699, AG-014447, PF-01367338, PF01367338, Rucaparib phosphate, Rucaparib

---

Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4^oC desiccated, or store DMSO solution at -20^oC.

---

Reference:

1.	"Phase II trial of the Poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA1 and 2 mutated advanced ovarian and breast cancer" Cancer Research UK / Newcastle Univ. Abstract 3104
2.	Thomas et al., Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer. Ther. 2007, 6(3), 945-956. Pubmed ID:17363489
3.	Daniel et al., Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin. Cancer Res. 2009, 15(4), 1241-1249. Pubmed ID:19174487

---

Other Information:

Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.

Cellagen Technology 公司位于美国加州San Diego，该公司致力于干细胞相关产品的研发和生产。基于多年为世界*的生物公司提供OEM产品的经验，目前Cellagen Technology公司利用自身优势，拓展了原有产品线，推出了以StemRegenin 1（SR1）为代表的多种自有品牌产品。 NamePriceCat # （Powder）Cat # （10 mM in DMSO）Pathway/Target7,8-Dihydroxyflavone1173C7181-10N/ATrkBA7696622023C2769-10N/AAMPKA83-011513C2831-2C2831-2sTGF-β/ALK4,5,7Abiraterone1853C2247-2C2247-2sP450-CYP17BEZ235833C2392-2C2392-2sPI3K, mTORBIX-012941513C2491-5C2491-5sEpigenetics/G9a HMTCHIR990213553C2447-2C2447-2sGSK3β CP-6905501343C2716-2C2716-2sJAK1,2,3Cyclopamine2193C2925-2C2925-2sHedgehog/SmoDAPT1853C3178-5C3178-5sNotch/γ-secretaseForskolin1853C3677-10N/AAdenylate cyclaseFTY7201173C3897-5C3897-5sS1P receptorsGDC-09411513C4321-5C4321-5sPI3KHh-Ag1.53043C4412-2C4412-2sHedgehog/SmoINCB0184241853C4622-2C4622-2sJAK1/2IWP-31853BackorderBackorderWntKHS1011853C5471-5C5471-5sNeural differentiationLDE2252363C5332-2C5332-2sHedgehog/SmoLDN-1931893723C5361-2C5361-2sBMP/ALK2,3Leukadherin-1#VALUE!C5385-2C5385-2sCD11b, CD18LY2940022193C5929-5C5929-5sPI3KP7C32363C7723-10N/Aneurogenic, neuroprotectivePD03259013723C7303-2C7303-2sMEK1, MEK2PD03329912193C7306-2C7306-2sCdk4, Cdk6PS481343C7748-5C7748-5sPDK1Pyrintegrin3383C7974-1C7974-1sES cell survivalR4062193C7406-2C7406-2sSykR7883723C7788-5C7788-5sSykRapamycin2193C7272-5C7272-5smTORReversine1173C7383-2C7383-2sA3 Adenosine ReceptorRO49290972703C7649-2C7649-2sNotch/γ-secretaseSB4315421513C7243-5C7243-5sTGF-β/ALK4,5,7SF16703723C7316-2C7316-2spTENSitagliptin1513C7482-5C7482-5sDPP-4SRT17202363C7781-2C7781-2sSIRT1StemRegenin1 （SR1）3723C7710-1C7710-1sAryl hydrocarbon receptorSU54022703C7854-1C7854-1sFGFRThiazovivin3553C8442-1C8442-1sROCKUrsolic Acid1853C8776-10N/ASTAT3VX-6801173C8916-10N/AAurora kinaseWnt-C592703C7641-2C7641-2sWntXAV9392703C9289-2C9289-2sWntY-276321853C9127-2C9127-2sROCKhuman Activin A5423P4228-1031910 µg37383P4228-1002199100 µghuman BMP-4 3723P4267-1021910 µg25483P4267-1001499100 µghuman bFGF 3383P4234-5019950 µg23783P4234-5001399500 µgmouse LIF 3383P6543-1019910 µg23783P6543-1001399100 µghuman Wnt-3a 3723P4968-1021910 µg